CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Mirabegron dose not specified in trial documentAI-extracted
Key inclusion· 4
  • Single unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter
  • Serum creatinine within normal range
  • Ability to tolerate oral fluids and oral pain medication
  • Willingness to follow-up in Urology Clinic in approximately 30 days and undergo ureteroscopic extraction if stone does not pass
Key exclusion· 9
  • Age less than 18 years
  • Multiple stones or solitary kidney or horseshoe kidney
  • History of ureteral surgery or previous endoscopic procedure
  • Allergy to mirabegron

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02744430
NCT02744430Phase 2Completed

A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02)

Baylor College of Medicine·interventional·Posted Apr 20, 2016·Updated Apr 26, 2022

In Brief

A Phase 2 clinical trial evaluating Mirabegron and Placebo for Ureteral Obstruction and Flank Pain. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography) scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 20, 2016
Enrollment StartJul 22, 2017
Primary CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.2 years ago

Interventions

Mirabegrondrug

Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.

Placeboother

Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.